Posted: Tuesday, February 7, 2023
An article published in JAMA Oncology presented findings from a study examining the cost-effectiveness of prostate cancer screening using MRI with combined targeted and standard biopsies compared with standard biopsies alone among men between the ages of 55 and 69. Tobias Nordström, MD, PhD, of the Karolinska Institutet, Stockholm, and colleagues reported that MRI-based screening with combined targeted and standard biopsies was associated with reduced lifetime prostate cancer–related deaths. They also reported an incremental cost-effectiveness ratio of U.S. $53,736 per quality-adjusted life-year gained compared with no screening. Additional findings revealed that compared with prostate-specific antigen (PSA) screening, MRI-based screening reduced the number of both lifetime biopsies and overdiagnosis by approximately 50%.
A total of 1,532 men between the ages of 55 and 69 were included in this study. All participants were from Sweden; 603 were randomly assigned to the standard arm and 929 were randomly assigned to the experimental arm. A microsimulation model was used to evaluate the no-screening and screening strategies among participants.
Findings revealed that compared with no screening, the screening strategies were associated with reduced lifetime prostate cancer–related deaths by 6% to 9%. Additionally, screening with MRI and the combined biopsies resulted in an incremental cost-effectiveness ratio of U.S. $53,736, which is classified as moderate cost per quality-adjusted life-years gained in Sweden. Relative to screening with standard biopsies alone, MRI-based screening reduced the number of both lifetime biopsies and overdiagnosis by approximately 50% and had a high probability of being cost-effective compared with traditional PSA screening. Based on these findings, the study authors concluded that MRI-based screening may be considered for early detection of prostate cancer in Sweden.
Disclosure: For full disclosures of the study authors, visit jamanetwork.com.